Venetoclax: Preliminary Phase Ib data

Preliminary data from 17 patients with relapsed or refractory CLL in the open-label, U.S. and U.K. Phase Ib GP28331 trial showed that 100-400 mg/day doses of oral venetoclax plus Gazyva obinutuzumab ...